Keytruda-Padcev approval by the European Commission on October 21, 2026, expands Merck’s bladder cancer treatment regimen to adults with resectable muscle-invasive disease regardless of eligibility for cisplatin chemotherapy. The combination is given before surgery and continued afterward, although commercial availability will depend on national reimbursement procedures.
Key Takeaways
- The approval covers treatment before and after surgery, regardless of cisplatin eligibility.
- The supporting Phase 3 trial showed a 47% reduction in the risk of disease progression, recurrence or death.
- Marketing authorization covers the EU, Iceland, Liechtenstein and Norway, but local access timing will vary.
Table of Contents
- Keytruda-Padcev approval broadens the eligible population
- Trial evidence compares the regimen with chemotherapy and surgery
- Reimbursement remains the next step for commercial access
- Conclusion
Keytruda-Padcev approval broadens the eligible population
Merck’s European approval announcement describes a regimen combining Keytruda, its PD-1 immune checkpoint inhibitor, with Padcev, the antibody-drug conjugate developed by Pfizer and Astellas. Treatment begins before radical cystectomy, the operation to remove the bladder, and continues after surgery.
Merck said this is the first and only PD-1 inhibitor plus antibody-drug conjugate regimen approved in the EU for muscle-invasive bladder cancer regardless of cisplatin eligibility. The decision also covers Keytruda SC, the subcutaneous formulation.
The broader eligibility matters because cisplatin-based chemotherapy is not suitable for every patient. Merck estimates that up to half of patients with muscle-invasive bladder cancer cannot receive cisplatin and face limited treatment options.
| Item | Details |
|---|---|
| Trial enrollment | 808 patients, randomized 1:1. |
| Combination group | 405 patients assigned to Keytruda plus Padcev and surgery. |
| Control group | 403 patients assigned to gemcitabine plus cisplatin before surgery, followed by observation. |
| Primary outcome assessment | Event-free survival assessed by blinded independent central review. |
Trial evidence compares the regimen with chemotherapy and surgery
The decision was based on the Phase 3 KEYNOTE-B15 trial, also called EV-304, conducted in collaboration with Pfizer and Astellas. It compared the combination given around surgery with chemotherapy before surgery in previously untreated patients eligible for cisplatin.
The combination reduced the relative risk of event-free-survival events—disease progression, recurrence or death—by 47%. The trial also showed a 35% reduction in mortality risk compared with chemotherapy and surgery.
These are relative risk reductions, not percentage-point changes in survival rates. The trial population was cisplatin-eligible, while the approved indication covers adults regardless of their eligibility for that chemotherapy.
Reimbursement remains the next step for commercial access
The authorization permits marketing for this indication in all 27 EU member states, as well as Iceland, Liechtenstein and Norway. It does not establish a single launch date across those markets: Merck said availability in individual countries depends on several factors, including completion of national reimbursement procedures.
For Merck, the decision expands an approved use of its oncology medicine rather than establishing an immediate revenue contribution. The company’s announcement did not quantify expected sales from the expanded European indication.
Conclusion
The approval broadens the European treatment setting for Keytruda and Padcev. The next step to watch is country-level commercial availability as national reimbursement procedures are completed.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
